Metabolic dysfunction-associated liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of liver-related morbidity and mortality, affecting one-third-of the global population. According to a recent meta-analysis, global incidence of MASLD is 4.6 per 100 person years [1]. In the Western world, decompensated cirrhosis and hepatocellular disease due to underlying MASLD have become a major indication for liver transplantation [2]. Also, concomitant MASLD is a risk factor for progressive liver disease in patients with chronic liver disease due to other causes.
